Determinants of racial disparity in the prescription of oral anticoagulants and future risk of thromboembolic stroke in patients newly diagnosed with atrial fibrillation

Oral anticoagulation reduces thromboembolic events associated with atrial fibrillation, yet 50% of patient with atrial fibrillation are not prescribed anticoagulants. Recent studies, including our preliminary findings, showed significant racial disparities in the prescribing of anticoagulants even after accounting for access to care, health insurance, and stroke risk factors. In this study, we will evaluate new factors that explain anticoagulant under-prescription, racial disparities in the prescription of anticoagulants, and incidence of stroke among patients newly diagnosed with atrial fibrillation.

Principal Investigator:
Yacob Tedla, PhD

Co-Investigators:
Abel Kho, MD
Philip Greenland, MD
Rod Passman, MD

Funding:
Funding for this project is provided by Bristol-Myers Squibb and Pfizer. Grant Number: CV185-767.

Timeline:
2020 – 2022